Targeted nonviral gene therapy in prostate cancer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Prostate cancer is the second most widespread cancer in men worldwide. Treatment choices are limited to prostatectomy, hormonal and radiotherapy that commonly have deleterious side effects and vary in their efficacy, depending on the stage of the disease. Among novel experimental strategies, gene therapy holds great promise for the treatment of prostate cancer. However, its use is currently limited by the lack of delivery systems able to selectively deliver the therapeutic genes to the tumors after intravenous administration without major drawbacks. To remediate to this problem, a wide range of non-viral delivery approaches have been developed to specifically deliver DNA-based therapeutic agents to their site of action. This review provides an overview of the various non-viral delivery strategies and gene therapy concepts used to deliver therapeutic DNA to prostate cancer cells, and focuses on the recent therapeutic advances being made so far.
LanguageEnglish
Pages5753—5767
Number of pages15
JournalInternational Journal of Nanomedicine
Volume13
DOIs
Publication statusPublished - 25 Sep 2018

Fingerprint

Gene therapy
Genetic Therapy
Prostatic Neoplasms
DNA
Radiotherapy
Tumors
Genes
Cells
Therapeutics
Prostatectomy
Intravenous Administration
Neoplasms

Keywords

  • prostate cancer therapy
  • gene delivery
  • tumor targeting
  • nanomedicine

Cite this

@article{04dd644ca3bf44f4b2e9b45f294712cc,
title = "Targeted nonviral gene therapy in prostate cancer",
abstract = "Prostate cancer is the second most widespread cancer in men worldwide. Treatment choices are limited to prostatectomy, hormonal and radiotherapy that commonly have deleterious side effects and vary in their efficacy, depending on the stage of the disease. Among novel experimental strategies, gene therapy holds great promise for the treatment of prostate cancer. However, its use is currently limited by the lack of delivery systems able to selectively deliver the therapeutic genes to the tumors after intravenous administration without major drawbacks. To remediate to this problem, a wide range of non-viral delivery approaches have been developed to specifically deliver DNA-based therapeutic agents to their site of action. This review provides an overview of the various non-viral delivery strategies and gene therapy concepts used to deliver therapeutic DNA to prostate cancer cells, and focuses on the recent therapeutic advances being made so far.",
keywords = "prostate cancer therapy, gene delivery, tumor targeting, nanomedicine",
author = "Najla Altwaijry and Sukrut Somani and Christine Duf{\`e}s",
year = "2018",
month = "9",
day = "25",
doi = "10.2147/IJN.S139080",
language = "English",
volume = "13",
pages = "5753—5767",
journal = "International Journal of Nanomedicine",
issn = "1176-9114",

}

Targeted nonviral gene therapy in prostate cancer. / Altwaijry, Najla; Somani, Sukrut; Dufès, Christine.

In: International Journal of Nanomedicine, Vol. 13, 25.09.2018, p. 5753—5767.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeted nonviral gene therapy in prostate cancer

AU - Altwaijry, Najla

AU - Somani, Sukrut

AU - Dufès, Christine

PY - 2018/9/25

Y1 - 2018/9/25

N2 - Prostate cancer is the second most widespread cancer in men worldwide. Treatment choices are limited to prostatectomy, hormonal and radiotherapy that commonly have deleterious side effects and vary in their efficacy, depending on the stage of the disease. Among novel experimental strategies, gene therapy holds great promise for the treatment of prostate cancer. However, its use is currently limited by the lack of delivery systems able to selectively deliver the therapeutic genes to the tumors after intravenous administration without major drawbacks. To remediate to this problem, a wide range of non-viral delivery approaches have been developed to specifically deliver DNA-based therapeutic agents to their site of action. This review provides an overview of the various non-viral delivery strategies and gene therapy concepts used to deliver therapeutic DNA to prostate cancer cells, and focuses on the recent therapeutic advances being made so far.

AB - Prostate cancer is the second most widespread cancer in men worldwide. Treatment choices are limited to prostatectomy, hormonal and radiotherapy that commonly have deleterious side effects and vary in their efficacy, depending on the stage of the disease. Among novel experimental strategies, gene therapy holds great promise for the treatment of prostate cancer. However, its use is currently limited by the lack of delivery systems able to selectively deliver the therapeutic genes to the tumors after intravenous administration without major drawbacks. To remediate to this problem, a wide range of non-viral delivery approaches have been developed to specifically deliver DNA-based therapeutic agents to their site of action. This review provides an overview of the various non-viral delivery strategies and gene therapy concepts used to deliver therapeutic DNA to prostate cancer cells, and focuses on the recent therapeutic advances being made so far.

KW - prostate cancer therapy

KW - gene delivery

KW - tumor targeting

KW - nanomedicine

UR - https://www.dovepress.com/international-journal-of-nanomedicine-journal

U2 - 10.2147/IJN.S139080

DO - 10.2147/IJN.S139080

M3 - Article

VL - 13

SP - 5753—5767

JO - International Journal of Nanomedicine

T2 - International Journal of Nanomedicine

JF - International Journal of Nanomedicine

SN - 1176-9114

ER -